Evidence map›Paper›PMID 34838196›Full record

ArticleThe Lancet. Public health2021

Temporal trend and attributable risk factors of stroke burden in China, 1990-2019: an analysis for the Global Burden of Disease Study 2019.

Qingfeng Ma, Rui Li, Lijun Wang, Peng Yin, Yuan Wang, Chuming Yan, Yi Ren, Zhengmin Qian, Michael G Vaughn, Stephen Edward McMillin and 8 more

4 registry-linked trialsAbstract read
In one paragraph

Article in The Lancet. Public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 533 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
533citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07335107 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion (RESCUE-AS): A Multicenter, Randomized, Open Label, Blinded Endpoint Study

TypeinterventionalSponsorBeijing Tiantan HospitalRan2026 to 2027Enrolled564ConditionsAcute Ischemic StrokeArmsIntravenous Tirofiban, Standard Medical Therapy
NCT07338175 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Minocycline in Patients With Acute Spontaneous Intracerebral Hemorrhage: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase III Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2026 to 2028Enrolled1,192ConditionsIntracerebral HemorrhageArmsMinocycline hydrochloride capsules, Placebo capsules of Minocycline hydrochloride capsules
NCT07353658 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Effect of Intermittent Versus Continuous Enteral Feeding on Outcomes in Severe Stroke: An Exploratory Study

TypeinterventionalSponsorXijing HospitalRan2026 to 2026Enrolled60ConditionsSevere Stroke, Enteral NutritionArmsIntermittent Enteral Feeding, Continuous Enteral Feeding
NCT07754942 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Local-to-Systemic Inflammatory Biomarker Gradients and 90-Day Functional Outcomes in Patients With Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion Undergoing Mechanical Thrombectomy: A Prospective Observational Cohort Study

TypeobservationalSponsorZhongshan Hospital Xiamen UniversityRan2026 to 2029Enrolled50ConditionsAcute Ischemic Stroke, Large Vessel OcclusionArmsProspective Mechanical Thrombectomy Cohort
3 · Its place in the literature

Who cites it

533 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Effectiveness of intermittent theta burst stimulation (iTBS) on Post-Stroke motor dysfunction: A Meta-Analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Digital Therapeutics in China: Comprehensive Review.Journal of medical Internet research · 2025
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Influence ofAnnals of medicine · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

473 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Qingfeng MaDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Rui LiDepartment of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.
Lijun WangNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Peng YinNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuan WangDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China; National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Chuming YanDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Yi RenDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Zhengmin QianDepartment of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, MO, USA.
Michael G VaughnSchool of Social Work, College for Public Health and Social Justice, Saint Louis University, Saint Louis, MO, USA.
Stephen Edward McMillinSchool of Social Work, College for Public Health and Social Justice, Saint Louis University, Saint Louis, MO, USA.
Simon I HayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Mohsen NaghaviInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Miao CaiDepartment of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.
Chongjian WangDepartment of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China.
Zilong ZhangDepartment of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.
Maigeng ZhouNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Hualiang LinDepartment of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.
Yin YangDepartment of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China. Electronic address: yangyin3@mail.sysu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnderstanding the temporal trend of the disease burden of stroke and its attributable risk factors in China, especially at provincial levels, is important for effective prevention strategies and improvement. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is to investigate the disease burden of stroke and its risk factors at national and provincial levels in China from 1990 to 2019.

methodsFollowing the methodology in the GBD 2019, the incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of stroke cases in the Chinese population were estimated by sex, age, year, stroke subtypes (ischaemic stroke, intracerebral haemorrhage, and subarachnoid haemorrhage), and across 33 provincial administrative units in China from 1990 to 2019. Attributable mortality and DALYs of underlying risk factors were calculated by a comparative risk assessment.

findingsIn 2019, there were 3·94 million (95% uncertainty interval 3·43-4·58) new stroke cases in China. The incidence rate of stroke increased by 86·0% (73·2-99·0) from 1990, reaching 276·7 (241·3-322·0) per 100 000 population in 2019. The age-standardised incidence rate declined by 9·3% (3·3-15·5) from 1990 to 2019. Among 28·76 million (25·60-32·21) prevalent cases of stroke in 2019, 24·18 million (20·80-27·87) were ischaemic stroke, 4·36 million (3·69-5·05) were intracerebral haemorrhage, and 1·58 million (1·32-1·91) were subarachnoid haemorrhage. The prevalence rate increased by 106·0% (93·7-118·8) and age-standardised prevalence rate increased by 13·2% (7·7-19·1) from 1990 to 2019. In 2019, there were 2·19 million (1·89-2·51) deaths and 45·9 million (39·8-52·3) DALYs due to stroke. The mortality rate increased by 32·3% (8·6-59·0) from 1990 to 2019. Over the same period, the age-standardised mortality rate decreased by 39·8% (28·6-50·7) and the DALY rate decreased by 41·6% (30·7-50·9). High systolic blood pressure, ambient particulate matter pollution exposure, smoking, and diet high in sodium were four major risk factors for stroke burden in 2019. Moreover, we found marked differences of stroke burden and attributable risk factors across provinces in China from 1990 to 2019.

interpretationThe disease burden of stroke is still severe in China, although the age-standardised incidence and mortality rates have decreased since 1990. The stroke burden in China might be reduced through blood pressure management, lifestyle interventions, and air pollution control. Moreover, because substantial heterogeneity of stroke burden existed in different provinces, improved health care is needed in provinces with heavy stroke burden.

fundingNational Key Research and Development Program of China and Taikang Yicai Public Health and Epidemic Control Fund.

Indexed as

Cost of IllnessPopulation HealthChinaDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseHumansIncidenceMaleMortalityPrevalenceRisk FactorsStroke

Identifiers

PMID34838196
PMCPMC9047702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.